Literature DB >> 24048781

The epidermal growth factor receptor conundrum.

Jason A Wilken1, Andre T Baron, Nita J Maihle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 24048781      PMCID： PMC3346883          DOI： 10.1002/cncr.25805

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  16 in total

1.  Cancer genetics. Test could yield improved colon cancer detection.

Authors:  J Marx
Journal:  Science       Date:  1992-04-03       Impact factor: 47.728

2.  Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.

Authors:  J L Reiter; D W Threadgill; G D Eley; K E Strunk; A J Danielsen; C S Sinclair; R S Pearsall; P J Green; D Yee; A L Lampland; S Balasubramaniam; T D Crossley; T R Magnuson; C D James; N J Maihle
Journal:  Genomics       Date:  2001-01-01       Impact factor: 5.736

3.  Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.

Authors:  J Codony-Servat; J Albanell; J C Lopez-Talavera; J Arribas; J Baselga
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

4.  Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain.

Authors:  A T Baron; B K Huntley; J M Lafky; J L Reiter; J Liebenow; D J McCormick; S C Ziesmer; P C Roche; N J Maihle
Journal:  Hybridoma       Date:  1997-06

Review 5.  Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.

Authors:  Zacharenia Saridaki; Vassilis Georgoulias; John Souglakos
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

6.  Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Authors:  Andre T Baron; Elsa M Cora; Jacqueline M Lafky; Cecelia H Boardman; Marites C Buenafe; Alfred Rademaker; Dachao Liu; David A Fishman; Karl C Podratz; Nita J Maihle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-02       Impact factor: 4.254

7.  Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Authors:  A T Baron; J M Lafky; C H Boardman; S Balasubramaniam; V J Suman; K C Podratz; N J Maihle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-02       Impact factor: 4.254

8.  Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.

Authors:  Vanesa Gregorc; Giovanni Luca Ceresoli; Irene Floriani; Anna Spreafico; Katia Bruna Bencardino; Vienna Ludovini; Lorenza Pistola; Zhasmina Mihaylova; Francesca Romana Tofanetti; Massimiliano Ferraldeschi; Valter Torri; Federico Cappuzzo; Lucio Crinò; Maurizio Tonato; Eugenio Villa
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

Review 9.  Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta.

Authors:  Jill L Reiter; Nita J Maihle
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

10.  A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.

Authors:  E A Perez; L Geeraerts; V J Suman; A A Adjei; A T Baron; A K Hatfield; N Maihle; J C Michalak; S A Kuross; J W Kugler; J M Lafky; J N Ingle
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976
View more
  9 in total

1.  Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

Authors:  Jason A Wilken; Andre T Baron; Ramsey A Foty; Daniel J McCormick; Nita J Maihle
Journal:  Biochemistry       Date:  2011-04-27       Impact factor: 3.162

Review 2.  The emerging era of genomic data integration for analyzing splice isoform function.

Authors:  Hong-Dong Li; Rajasree Menon; Gilbert S Omenn; Yuanfang Guan
Journal:  Trends Genet       Date:  2014-06-17       Impact factor: 11.639

Review 3.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

4.  Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma.

Authors:  Christopher Fung; Pei Zhou; Sonali Joyce; Kerry Trent; Jian-Min Yuan; Jennifer R Grandis; Joel L Weissfeld; Marjorie Romkes; Daniel E Weeks; Ann Marie Egloff
Journal:  Cancer Lett       Date:  2014-12-12       Impact factor: 8.679

Review 5.  A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.

Authors:  Gilbert S Omenn; Yuanfang Guan; Rajasree Menon
Journal:  J Proteomics       Date:  2014-05-05       Impact factor: 4.044

Review 6.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

7.  Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.

Authors:  Malgorzata Banys-Paluchowski; Isabell Witzel; Sabine Riethdorf; Brigitte Rack; Wolfgang Janni; Peter A Fasching; Erich-Franz Solomayer; Bahriye Aktas; Sabine Kasimir-Bauer; Klaus Pantel; Tanja Fehm; Volkmar Müller
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

8.  Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.

Authors:  Martin Pool; Arjan Kol; Marjolijn N Lub-de Hooge; Christian A Gerdes; Steven de Jong; Elisabeth G E de Vries; Anton G T Terwisscha van Scheltinga
Journal:  Oncotarget       Date:  2016-10-18

9.  Bile acids target proteolipid nano-assemblies of EGFR and phosphatidic acid in the plasma membrane for stimulation of MAPK signaling.

Authors:  Hong Liang; Mary K Estes; Huiling Zhang; Guangwei Du; Yong Zhou
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.